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Abstract
This paper explores the evolution of the conceptualization of schizophrenia. Specifically, the paper focuses
upon negative symptomology and the emphasis that such symptoms have garnered over time. Negative
symptoms are associated with higher levels of impairment and poorer outcomes in schizophrenia. Historically,
negative symptoms were the core feature of schizophrenia in the early conceptualizations of Kraepelin and
Bleuler, holding precedence until the emergence of Schneiderian theory in the 1970's. The focus on negative
symptoms then changed to positive symptoms; which is still the key focus today. This shift in emphasis has
resulted in a dearth of knowledge and treatment for such symptoms and as such an area requiring further
research. The paper also addresses the conceptual changes in the nosology of Schizophrenia and other
psychosis with respect to the Diagnostic and Statistical Manual of Mental Disorders-5. Further the potential
for the clinical assessment interview for negative symptoms to facilitate understanding and treatments for
negative symptomology in schizophrenia is also discussed.
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Introduction
Schizophrenia is a chronic and debilitating condition with 
the frequently reported prevalence rate of 1% or 1 in 100 
individuals being affected, internationally.[1-3] Schizophrenia 
is a devastating condition for those that are afflicted as 
well as their families and friends. Further schizophrenia, 
also exacts a tremendous toll upon society, economically 
through service utilization, and lost productivity.[4] As well 
as impacting upon societal outcomes such as violence, 
substance misuse, homelessness, and suicide within the 
community.[5]
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ABSTRACT
This paper explores the evolution of the conceptualization of schizophrenia. Specifically, the paper focuses upon negative 
symptomology and the emphasis that such symptoms have garnered over time. Negative symptoms are associated with higher levels 
of impairment and poorer outcomes in schizophrenia. Historically, negative symptoms were the core feature of schizophrenia in the 
early conceptualizations of Kraepelin and Bleuler, holding precedence until the emergence of Schneiderian theory in the 1970’s. The 
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Schizophrenia is a complex condition having a multiplicity 
of symptoms that impact upon the core of an individual’s 
being; affecting their cognition, emotions, and behaviors.[6,7] 
That is, individuals with schizophrenia may have problems 
perceiving what is real from what is not real (delusions and 
hallucinations). They may behave in a bizarre manner ranging 
from childlike behavior to unprovoked agitation (disorganized 
behavior). They could completely lack any motivation for 
pursing any goal-directed activities (avolition). Further, they 
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may have problems with emotional expression, with an 
inability to express emotion (affective flattening or blunted 
affect) or the expression of contextually inappropriate 
emotions (inappropriate affect).
Although schizophrenia has been a focus of scientific 
investigation for more than a century,[8,9] a dearth of 
knowledge regarding the structure, nosology, and treatment 
of the disorder pervades.[10] This scarcity of knowledge 
is especially prevalent in regards to the symptoms that 
reflect a diminution of normal functioning termed negative 
symptoms.[11,12] Approximately, 28-36% of individuals with 
schizophrenia comprise a latent group of individuals who 
experience severe and enduring negative symptoms.[13]
Arango and Carpenter[14] ascertain that the most common 
negative symptoms are alogia, affective flattening (blunted 
affect), anhedonia, asociality, avolition, and apathy. Alogia is 
defined as a poverty of speech either in frequency or content. 
Affective flattening or blunted affect refers to a diminution of 
emotional expression. Anhedonia pertains to the inability to 
experience pleasure while asociality refers to a general lack 
of interest in social relationships. Avolition is defined as a 
general lack of motivation, and apathy pertains to a lack of 
interest in general.[14]
The presence of negative symptoms in schizophrenia has 
consistently been found to result in greater functional 
impairment and poorer illness outcomes for those that are 
afflicted.[15-17] Further, there are no psychopharmaceutical 
agents despite the multitude of them or psychosocial 
interventions that effectively treat negative symptomology.[6,18]
Even though the dearth of knowledge and the impact of 
negative symptoms are clear; the focus on negative symptoms 
in schizophrenia has varied significantly over time. This article 
aims to trace the theorizing pertaining to negative symptoms 
in schizophrenia over time. Specifically, this article will review 
historical and contemporary conceptualizations of schizophrenia 
with a focus on the inherent importance of negative symptoms 
in the nomenclature of schizophrenia. The recent nomenclature 
of negative symptomology in schizophrenia specifically in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 
and the clinical assessment interview for negative symptoms 
(CAINS) will be discussed with a focus on the potential impact 
on the understanding and treatment of negative symptomology 
in schizophrenia.
The Past Nosology of Schizophrenia
Accounts of psychotic conditions akin to schizophrenia 
spectrum disorders are evident in literature as far back as 
pharaonic Egypt; predating the birth of Christ.[6] The first 
conceptual framework of a schizophrenia-like condition 
was described by Kraepelin in 1887.[6,9] Kraepelin[9] termed 
this condition dementia praecox and postulated that 
the condition was marked by reduced cognitive activity, 
diminished interest, and lethargy. Further, Kraepelin[9] viewed 
schizophrenia (dementia praecox) as a distinct singular 
disease entity.
Following Kraepelin, Bleuler[8] further theorized about the 
condition known as dementia praecox, which he renamed 
as schizophrenia in 1911. Bleuler[8] conceptualized 
schizophrenia as a group of disorders as oppose to a 
singular disease entity due to the heterogeneity of symptoms 
evident in different individuals. Bleuler[8] further outlined 
the nosology of schizophrenia, delineating the core of the 
disorder; the fundamental symptoms that he believed were 
pathognomonic to schizophrenia. In addition, Bleuler[8] also 
described a secondary set of symptoms, that is, symptoms 
that he believed were not unique to schizophrenia but 
were also apparent in other disorders. That is, Bleuler[8] 
ascertained that schizophrenia was a disturbance of 
association, affectivity, attention, and volition.
Kraepelin[9] and Bleuler’s[8] conception of schizophrenia 
differed through their preferred mode of defining the 
disorder with; Kraepelin’s[9] definition being based on an 
epidemiological stance and Bleuler[8] favoring a nosological 
account of schizophrenia.[10,19] Conceptually, their definitions 
of the disorder were highly congruent.[8,9] Both Kraepelin[9] 
and Bleuler’s[8] notion of schizophrenia emphasized the 
loss or diminution of cognitive, affective, and volitional 
capacities. Hence, both eminent theorists of schizophrenia 
conceptualized the core of schizophrenia to be negative 
symptomology.
This view of schizophrenia remained the prominent 
view until the 1960’s when the emphasis shif ted 
toward symptoms reflective of a disturbance of reality 
such as delusions and hallucinations.[6,20] Hence, the 
conceptualization of schizophrenia changed to focus on 
positive symptomology. This shift in focus occurred for 
a number of related reasons namely one primary reason 
pertained to improving the reliability of the diagnosis 
of the disorder.[6] As positive symptoms reflective of a 
reality disturbance are much more easily identifiable being 
either present or absent, as oppose to the diminution 
of functioning apparent in the negative symptomology 
described by Kraepelin[9] and Bleuler.[8]
Further stimulating this change in the conceptualization 
of the core of schizophrenia was the development and 
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utilization of the first antipsychotic, chlorpromazine[21] 
coupled with the emergence of Schneiderian theory.[22] 
Specifically, chlorpromazine, akin to most antipsychotics 
(especially the first generation antipsychotics), was effective 
in the treatment of positive symptoms associated with 
reality disturbances or an excess of functioning as oppose to 
symptoms reflective of a diminution of “normal” functional 
capacities or negative symptoms.
Schneider[22] proposed 11 first-rank symptoms of 
schizophrenia; however, Schneider’s[22] view differed 
significantly from that of Kraepelin[9] and Bleuler’s[8] 
conception. Although akin to Bleuler,[8] Schneider[22] 
believed the symptoms he described were pathognomonic 
to schizophrenia. The 11 first-rank symptoms described 
by Schneider[22] pertained to disturbances of reality and 
perception being much more easily identifiable than 
symptoms pertaining to a diminution of functioning. This 
significantly changed the symptomology that were viewed 
as pathognomonic to schizophrenia. This shift was accepted 
with alacrity and quickly became the favored nomenclature 
of schizophrenia.[6,19,23,24]
A few theorists continued to recognize the importance of 
negative symptomology.[25,26] With Andreasen[27] recognizing 
that although positive symptomology is readily identifiable, it 
is not the most fundamental characteristic of schizophrenia; 
hence, she developed the first scale for measuring negative 
symptomology in schizophrenia in 1983; the scale for 
the assessment of negative symptoms (SANS). This 
instrument offered the first operational definition of the 
negative symptomology construct.[27] The SANS measures 
the following negative symptoms: Alogia, affective blunting, 
avolition — apathy, anhedonia — asociality, and attentional 
impairment.[27] Attentional impairment is no longer viewed as 
a negative symptom of schizophrenia rather it is recognized 
as a cognitive symptom of schizophrenia, although negative 
symptoms and cognitive symptoms have been demonstrated 
to be related.[28]
Crow[25] defined two types of schizophrenia; Type I 
being associated with positive symptoms and Type II 
being associated with negative symptoms. Although the 
aforementioned types are not intended to be synonymous 
with positive and negative symptoms as they are based on 
a series of characteristics and not solely the predominance 
of positive and negative symptoms.[25,26] Crow[25] proposed 
the two dimensions of pathology in schizophrenia, one 
dimension being potentially amenable to treatment and 
the other associated with a deficit state, the latter being 
unchangeable by treatment and associated with poor long-
term outcomes.
Furthermore within this period, Carpenter et al. delineated 
the distinction between primary (or enduring) and secondary 
(nonenduring) negative symptoms. That is, enduring or 
deficit negative symptoms were postulated to result from 
the clinical core of schizophrenia.[26] Whereas secondary or 
nonenduring negative symptoms result from other influences 
such as positive symptoms, antipsychotic treatment, 
depression, and social deprivation and are generally more 
amenable to treatment.[26] Furthermore during this period, 
Kay et al.[29] developed the positive and negative syndrome 
scale to assess both positive and negative symptomology 
along with general psychopathology.
Although some theorists remained interested in negative 
symptomology, the primary focus upon a disturbance 
of reality and perception as the fundamental basis of 
schizophrenia has largely continued until today.[14] With the 
pervasiveness of this view, further reflected by the omission 
of negative symptoms associated with a diminution of 
“normal” functional capacities’ from classificatory systems 
until the DSM-IV.[14,30] Such a focus significantly impeded the 
development of knowledge pertaining to negative symptoms 
and, consequentially, has impacted on the development of 
treatments for the aforementioned symptomology.
The Present and Future Nosology 
of Schizophrenia
The DSM-IV-Text Revision (TR)[31] defines schizophrenia as 
a “disorder that lasts for at least 6 months and includes at 
least 1-month of active-phase symptoms (i.e., two or more 
of the following: Delusions, hallucinations, disorganized 
speech, grossly disorganized or catatonic behavior, negative 
symptoms).” Further, the DSM-IV-TR[31] also stipulates that 
these symptoms cause discernible social and occupational 
dysfunction.
The DSM-IV-TR[31] does incorporate the existence of negative 
symptoms into the classification of schizophrenia spectrum 
disorders with the DSM-IV-TR[31] including affective flattening, 
alogia, and avolition as negative symptoms. Anhedonia 
commonly recognized as a negative symptom is merely 
classified as an associated feature of schizophrenia in the 
DSM-IV-TR.[14,31] Further others[14] ascertain that in addition 
to the negative symptoms outlined in the DSM-IV-TR[31] 
asociality and apathy are also generally accepted as negative 
symptoms of schizophrenia and thus should be included 
as such.
The DSM-IV-TR[31] and the ICD-10[32] are comparable in the 
diagnosis of schizophrenia with; both making reference 
to negative symptomology and requiring the presence of 
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delusions and hallucinations for a diagnosis of schizophrenia. 
However, although both systems require 1-month of 
active-phase symptoms the ICD-10[32] only requires 1-month 
of symptoms in total for the diagnosis of schizophrenia in 
comparison to the DSM-IV-TR[31] that requires a 6 months 
duration of symptoms. Differentially, the ICD-10[32] places 
greater emphasis on Schneiderian first-rank symptoms 
and has a more detailed complex list of the symptoms of 
schizophrenia than the DSM-IV-TR.[31] However, the ICD-10[32] 
also places a greater emphasis upon negative symptomology 
as well; including a subtype of simple schizophrenia a purely 
negative variant of schizophrenia.[20]
Therefore, it is apparent that even though the study of negative 
symptoms has come back into favor in recent times[33,34] the 
study of the construct remains constrained by the most 
widely utilized classificatory system; the DSM-IV-TR.[35] With 
symptoms that were historically conceptualized as the core 
of schizophrenia; negative symptoms set aside in favor of 
a Schneiderian view of the schizophrenia spectrum.[36,37] 
Further, the nomenclature delineated in the DSM-IV-TR only 
captures a small subset of the clinical core of schizophrenia 
due to the stipulated severity (high) required of both 
primary negative and disorganized symptoms.[37] Parnas[37] 
asserts that this delineation impacts upon the diagnosis of 
nonparanoid schizophrenia cases.
In addition to the aforementioned issues with the nosology 
of schizophrenia as operationalized in the DSM-IV-TR, there 
are many who advocate that schizophrenia as characterized 
by enduring primarily negative symptoms is a distinct 
separate syndrome.[34,36] Being clinically distinguishable 
through several features including; distinct neuroanatomical 
features, asocial developmental pattern, reduced substance 
use, reduced depression and suicide.[36] Further, the 
dimensionality of psychopathology and negative symptoms, 
in particular, has also been highlighted.[34]
The DSM-IV-TR has now been superseded by the completion 
of the DSM-5.[38] Tandon and Carpenter[39] ascertain that 
there were only to be minor changes to the schizophrenia 
and other psychotic disorders nomenclature between the 
DSM-IV-TR and the DSM-5 however, the changes outlined 
may assist with overcoming some of the shortcomings of the 
predecessor classificatory system. Further Tandon et al.[40] 
ascertain that the DSM-IV definition of schizophrenia is 
retained in the DSM-5, however, there is further clarification 
of negative symptomology included in the DSM-5.
Significantly Schneiderian first-rank symptoms of 
schizophrenia are likely to receive less importance in the 
diagnosis of schizophrenia, although there was no mention 
of placing more emphasis on negative symptomology.[39] 
Further, there are no plans to expand the specific symptoms 
under the negative symptom construct to reflect all the 
symptoms that are commonly conceptualized as a negative 
symptom of schizophrenia.[14,39] Rather the terms diminished 
emotional expression, and avolition are utilized to capture 
the negative symptomology construct, along with alogia, 
anhedonia, and asociality.[38]
Further the traditional subtypes of schizophrenia 
(disorganized, paranoid, and catatonic) have been 
abandoned to reflect the fact that most people with 
schizophrenia have the symptomology associated with 
multiple subtypes of schizophrenia and move through the 
different subtypes over the duration of their illness.[40] Rather 
the heterogeneity of schizophrenia will be characterized by 
the incorporation of dimensional ratings of the different 
psychopathological domains of schizophrenia and psychotic 
spectrum disorders.[38,39] Each of the psychopathological 
domains is rated on a scale from 0; not present through 
to 4; severe.[38] This abandonment of the traditional subtypes 
and the acceptance of a dimensional approach may increase 
the heuristic value and clinical utility of the nosology. As 
the adoption of a dimensional approach aligns to reflect 
the heterogeneity of schizophrenia; thus increasing the 
pragmatic value of the diagnosis for both research and 
clinical practice alike.[21] Such an approach will also reduce 
the heterogeneity that is apparent in the traditional subtypes 
of schizophrenia.[41] Further, this approach to the diagnosis 
of schizophrenia has particular significance in regards to 
functional assessment. However, others have contended 
that the key strength of the DSM-IV criteria is its clinical 
utility and as such the DSM-5 should be even more superior 
for clinical usage,[35] through time and use it should become 
apparent whether the DSM-5 has increased clinical utility. In 
contrast, they also ascertain that the DSM continues to limit 
understanding and research into the schizophrenia construct 
through the atheoretical diagnostic criteria espoused.[35]
It still remains that more emphasis needs to be placed 
upon negative symptomology with the conceptual domains 
and relationships between the specific symptoms clearly 
delineated. Recently, the National Institute of Mental Health 
(NIMH) - measurement and treatment research to improve 
cognition in schizophrenia (MATRICS) released a consensus 
statement highlighting recommendations to assist with 
the development of treatments for negative symptoms in 
schizophrenia.[42] It is only with a clearer conceptualization 
as well as placing more importance upon these symptoms 
that advances can be made. However, Tarrier[43] noted 
that the NIMH-MATRICS consensus statement was biased 
toward the neurobiological mechanisms that underpin 
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negative symptomology and thus the development of 
psychopharmaceutical agents to the exclusion of psychosocial 
interventions. In addition, Tarrier[43] ascertained that further 
delineation and focus on the conceptual basis of negative 
symptomology would be beneficial in the development of 
both psychopharmaceutical and psychosocial treatments 
for negative symptoms in schizophrenia.
Recently, the collaboration to advance negative symptom 
assessment of schizophrenia (CANSAS) was established 
to develop a clinical assessment scale for negative 
symptomology in schizophrenia.[33,44,45] This working group 
has developed and commenced validating a measure 
for the clinical assessment of schizophrenia namely; 
the CAINS.[33,44,45] The CAINS was specifically designed 
to overcome the limitations inherent in the existing 
instruments.[45] Further, the development of the CAINS aims 
to promote innovative research into treatments for negative 
symptoms both pharmacological and psychosocial.[45] 
Along with advancing understanding pertaining to the 
underlying causes of schizophrenia as well as assisting 
with endeavors to forge and unite neuroscience based 
accounts of schizophrenia with other clinical and theoretical 
descriptions of schizophrenia.[45]
The CAINS offers immense hope to the assessment and 
treatment of negative symptomology in the future. Through 
a unique development and validation process the CANSAS 
has conducted initial validation of the CAINS, with the 
CAINS incorporating five core negative symptoms, namely 
asociality, avolition, anhedonia (both consummatory and 
anticipatory), blunted affect and alogia.[45] Initial validation 
procedures have demonstrated a two-factor model pertaining 
to experiential and expressive negative symptoms.[45]
It is hoped that the changes evident in the DSM-5 
schizophrenia criteria although only indirectly linked 
to negative symptomology, through less reliance upon 
Schneiderian first-rank symptoms of schizophrenia will 
increase awareness of negative symptomology. Similarly it 
is anticipated that the new instrument for the assessment of 
negative symptoms; the CAINS will promote the significance 
of the negative symptomology in schizophrenia and the 
necessity for a greater understanding of the construct, 
along with the development of effective treatments for such 
debilitating symptoms. Further, it is also hoped that the 
aforementioned changes that have the potential to facilitate 
a greater understanding of negative symptomology are also 
apparent in the forthcoming ICD-11.
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